Houses, townhouses, condos for sale in East Bay
Real Estate: Walnut Creek homes, Oakland Hills, Danville homes, Alameda County homes, Contra Costa County homes, Concord homes, Livermore, East Bay homes, Berkeley, San Ramon Danville Alamo homes, Pleasanton homes, Hayward homes, Orinda Moraga Lafayette homes, Walnut Creek Concord Pleasant Hill homes, Dublin homes, Orinda homes, Moraga homes, Lafayette homes, Antioch, Castro Valley homes, San Ramon homes, San Leandro, Pleasant Hill homes, San Lorenzo, Clayton, Alamo homes

World News   USA   California   Bay Area   San Francisco   North San Mateo County   South SF   Genentech (105)
Genentech Timeline Thursday, May 23 Bookmark and Share     Author
Search Bay Area News Atlas:
World News (13) USA (269) California (158) Bay Area (10) San Francisco (1869) North San Mateo County (165) South SF (123) Genentech (105)
2011 (1) 2010 (4) 2009 (13) 2007 (3) 2006 (8) 2005 (5) 2004 (5) 2003 (5) 2002 (2) 2001 (1)
Avastin (13) Herceptin (2) Lucentis (2)
Genentech on Wikipedia Genentech on Web
Real Estate
Chart Time by Topic
Avastin (13)   Roche (7)   South SF Merger and Acquisition (17)   South SF Bio Tech (38)   San Francisco Bio Tech (40)
Recent Summary.     Click for More >
No news/event found



     * Time by Topic
Genentech, 21st Century, Time by Topic
Time Bio Tech Merger and Acquisition Earnings Science & Education
2011 Your ad is here Your ad is here Your ad is here Your ad is here
2010
Panel doesn't back Avastin for cancer
Avastin delays ovarian cancer
Your ad is here Your ad is here
Panel doesn't back Avastin for cancer
FDA Approves Actemra Arthritis Drug
2009
FDA clears drug for kidney cancer
Axe falls at Genentech
Drug Raptiva pulled from market
Roche to take over Genentech for $47B
Roche-Genentech deal called close
Roche raises bid for Genentech
Roche launches $86.50-a-share bid
Roche revives takeover bid of Genentech
Axe falls at Genentech
Big leadership changes at Genentech
Roche to take over Genentech for $47B
Roche-Genentech deal called close
Roche raises bid for Genentech
Roche launches $86.50-a-share bid
Roche revives takeover bid of Genentech
Your ad is here
Roche touts Herceptin in stomach cancers
2008
Avastin linked to higher risk of clots
Retention plan to cost $371 million
Genentech rejects Roche's $43.7b bid
Roche Offers $44B For Remaining Shares
Bad news on cancer drug Rituxan
Court slashes $200 million from judgment
FDA Clears Avastin for Breast Cancer
Retention plan to cost $371 million
Genentech rejects Roche's $43.7b bid
Panel to ponder Roche takeover offer
4Q Profit Rises 6 Percent
Avastin linked to higher risk of clots
2007
FDA Panel Rejects Avastin, stock drops
3Q Profit Up 21 % On Cancer Drug Sales
Your ad is here
3Q Profit Up 21 % On Cancer Drug Sales
4Q Earnings Soar 75%
Your ad is here
2006
Genentech to acquire partner Tanox
Cancer drug review extended
Tony Blair Visits Genentech Headquarters
2Q Profit Soars to $531 Million
FDA approves blindness drug
Cancer Drug Trials Scaled Back
Genentech to acquire partner Tanox
2Q Profit Soars to $531 Million
Profit climbs by 48% in first quarter
Up 64% in quarter after good year
Cancer Drug Trials Scaled Back
2005
Profits Soar 73% in 2Q
Avastin helps those with breast cancer
Biotech giant's profit up 61%
4th best place to work for in U.S.
Your ad is here
Profits Soar 73% in 2Q
Biotech giant's profit up 61%
Profit surges, misses expectations by 1c
Avastin helps those with breast cancer
2004
Avastin helps sickest patients
Profits surge on drug sales
Profits surge on brisk cancer drug sales
FDA approves cancer fighter Avastin
Your ad is here
Profits surge on drug sales
Profits surge on brisk cancer drug sales
Profits surge on strong drug sales
Avastin helps sickest patients
2003
Biotech titan posts higher profits
Firm: Genentech refuses to share profits
Encouraging results with cancer drug
Your ad is here
Biotech titan posts higher profits
Your ad is here
2002
Big patent win vs. Chiron
Your ad is here Your ad is here Your ad is here

     * Time by Topic

Genentech Resources  

Neighbor News Timelines:
San Francisco Central San Mateo County North San Mateo County SFO Daly City San Bruno South SF Bay
Bay Area Bridges PG&E Brisbane Pacifica War on Terrorism San Bruno Explosion Visitacion Valley Caltrain
YouTube Colma 94005 94014 94015 94044 94066 94080
94112 94128 94134 Ingleside

Neighbor Real Estate:
East Bay Alameda County Contra Costa County Oakland Bay Area Freeways
Dublin Pleasanton Livermore East Contra Costa Hayward Castro Valley San Leandro Orinda Moraga Lafayette San Ramon Danville Alamo
Walnut Creek Concord Pleasant Hill Concord Danville Hayward Livermore
Pleasanton Walnut Creek East Oakland Antioch Castro Valley
Dublin Lafayette Moraga Orinda Pleasant Hill
San Leandro San Ramon Bay Area Bridges Chevron Alamo
Clayton San Lorenzo Diablo Dugard Case Mount Diablo Park
Blackhawk Rossmoor Chronicle Pavilion

Add a favorite (file a bookmark) to Genentech News Timeline

Please send feedback to: support@mapreport.com

Advertise on Genentech Page

Real Estate: 94506 homes, 94501, 94502, 94526 houses, 94509, 94531, 94582 homes, 94540, 94541, 94583 homes, 94542, 94543, 94595 houses, 94544, 94545, 94596 homes, 94546, 94552, 94597 homes, 94550, 94551, 94598 houses, 94557, 94577, 94518 homes, 94578, 94579, 94519 homes, 94608, 94662, 94520 houses, 94701, 94702, 94521 homes, 94703, 94704, 94522 homes, 94705, 94526, 94523 houses, 94706, 94707, 94524 homes, 94708, 94709, 94527 homes, 94710, 94712, 94582 houses, 94720, 94583 homes, 94566 houses, 94568 homes, 94588 houses
Houses, townhouses, condos for sale in East Bay
Legend  

XML

Details:

Apple names Levinson non-exec chair  Apple rewards the longtime Apple board member who chose it over Google when the technology giants began competing Panel doesn't back Avastin for cancer  The drug, which was developed by Roche's Genentech unit, failed to win a U.S. panel's backing for continued sales as a treatment for breast ... Avastin delays ovarian cancer  A late-stage clinical trial showed that Genentech's drug Avastin can delay the progression of recently-diagnosed ovarian cancer FDA Approves Actemra Arthritis Drug  Biotechnology company says the U.S. Food and Drug Administration has approved its new drug to treat rheumatoid arthritis FDA clears drug for kidney cancer

year 2011 Top ^

Nov.15

year 2010 Top ^

Nov.18  Genentech cutting 450 jobs in South SF
Jul.20
Jul.2
Jan.9

year 2009 Top ^

Aug.2
  Food and Drug Administration approved its cancer treatment Avastin for a new use, marking the sixth approval for the blockbuster drug
Jul.9 Axe falls at Genentech
  Anxiety rippled through Genentech as Roche began to cut rank-and-file jobs as it folds the South SF biotech firm into its global operations
Apr.15 Big leadership changes at Genentech Apr.8 Drug Raptiva pulled from market  The unit of drugmaker Roch is pulling the psoriasis treatment Raptiva off the U.S. market because of links to an often fatal brain infection Mar.26 Roche completes purchase of Genentech Mar.19 Roche touts Herceptin in stomach cancers Mar.12 Roche to take over Genentech for $47B
  Swiss giant agreed to buy the 44% of biotech pioneer that it doesn't already own, ending a long corporate struggle
 The $95-per-share deal brings Roche all of the sales of cancer drugs as well as its promising research pipeline. The deal offers $95 per share for the 44 percent of Genentech that Roche Holding AG doesn't already own
Mar.9 Roche-Genentech deal called close  Roche is reportedly willing to pay Genentech $95 a share, up from the $93, in what would be a $46.7 billion deal Mar.6 Roche raises bid for Genentech  Swiss drugmaker increased its offer to $93 per share. Genentech shares shot up to $90.05, gaining $8.41 or 10 percent Mar.3 Genentech replies to hostile Roche bid Feb.9 Roche launches $86.50-a-share bid  Swiss drugmaker officially launched its $42 billion hostile offer for the 44% of Genentech Inc. it doesn't already own Feb.6 Roche CEO: Offer for Genentech fair deal Jan.30 Roche revives takeover bid of Genentech  Swiss drugmaker, frustrated by stalled negotiations, plans a hostile takeover at a lower price than the $89 per share rejected in August

year 2008 Top ^

Nov.18 Avastin linked to higher risk of clots  A team of university researchers: Blockbuster cancer drug is linked to a significantly increased risk of blood clots in the veins Aug.21 Retention plan to cost $371 million Aug.17 Recruiters eye Genentech employees Aug.13 Genentech rejects Roche's $43.7b bid  Biotechnology giant rejected a buyout offer from its majority owner Roche but said it is open to a higher takeover bid Jul.31 Shareholders sue to halt Roche buyout Jul.25 Panel to ponder Roche takeover offer Jul.21 Roche Offers $44B For Remaining Shares  Roche Holding, which already owns 55.9%, was offering $43.7 billion to take over the remaining shares of Genentech Apr.30 Bad news on cancer drug Rituxan  Shares in Genentech sagged, after the company said Rituxan failed to curb symptoms of the debilitating autoimmune disorder Apr.24 Court slashes $200 million from judgment  The company has been ordered to pay $500 million to a Southern California hospital for failing to pay royalties Feb.22 FDA Clears Avastin for Breast Cancer
  A Genentech drug received federal approval, a surprise decision
Jan.14 4Q Profit Rises 6 Percent

year 2007 Top ^

Dec.5 FDA Panel Rejects Avastin, stock drops  Shares dropped nearly 9% after a panel of medical experts said FDA should deny approval of the company's blockbuster drug Oct.16 3Q Profit Up 21 % On Cancer Drug Sales Jan.10 4Q Earnings Soar 75%

year 2006 Top ^

Nov.11 Genentech to acquire partner Tanox Aug.12 Cancer drug review extended Jul.31 Tony Blair Visits Genentech Headquarters  Heavy hitters from biotech firms sat down for an extraordinary talk with British Prime Minister Jul.11 2Q Profit Soars to $531 Million Jul.1 FDA approves blindness drug Apr.12 Profit climbs by 48% in first quarter Feb.13 Cancer Drug Trials Scaled Back  Avastin only targets cancer, and leaves healthy cells alone Jan.11 Up 64% in quarter after good year

year 2005 Top ^

Jul.11 Profits Soar 73% in 2Q  The second quarter profit is fueled by continued strong drug sales. The results exceeded the estimate by 4 cents Apr.16 Avastin helps those with breast cancer Apr.12 Biotech giant's profit up 61% Jan.10 4th best place to work for in U.S. Profit surges, misses expectations by 1c

year 2004 Top ^

Nov.29 Avastin helps sickest patients Oct.6 Profits surge on drug sales Apr.7 Profits surge on brisk cancer drug sales Feb.26 FDA approves cancer fighter Avastin Jan.14 Profits surge on strong drug sales

year 2003 Top ^

Oct.8  Biotech titan posts higher profits Aug.15  Firm: Genentech refuses to share profits May.19 Encouraging results with cancer drug
  Avastin extended the lives of some of the colon cancer patients. Company's stock soaring nearly 45%
May.12  Arthritis drug fails key experiment May.9  Janitors will get health insurance

year 2002 Top ^

Sep.10  Stock plummets 9.7% Sep.7  Big patent win vs. Chiron

year 2001 Top ^

Oct.11  $400 million suit against Genentech